CCA Insights

Scientists developed prognostic models to help clinicians decide on the best treatment for patients with intrahepatic cholangiocarinoma.

Involving a multidisciplinary team in the management of cases of cholangiocarcinoma can improve outcomes and the patient experience.

Studies into the molecular underpinnings of cholangiocarcinoma open up opportunities for therapeutics for cholangiocarcinoma to be developed.

Although related anatomically, hepatocellular carcinoma and intrahepatic cholangiocarcinoma have key differences.

Targeting DDR as emerged as a promising strategy for developing cancer-specific therapies. Here, we discuss the use of DDR inhibitors in CCA.